Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Intravenous infusion (continuous) - standard hospital delivery method
Route
3 recommended
Sites
Once daily
Frequency
Preparation
Natriuretic Peptide (ANP) vial (lyophilized powder or solution)
Bacteriostatic water or sterile sodium chloride for reconstitution
Alcohol swabs for cleaning vial tops and injection sites
Appropriately sized syringes with fine-gauge needles (27-30 gauge)
Sharps disposal container
Pro tip
Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.
Mixing
Wash your hands thoroughly with soap and water. Gather all supplies on a clean, flat surface.
Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol swab. Let it air dry.
Draw the appropriate amount of bacteriostatic water into a sterile syringe.
Insert the needle into the vial at an angle, aiming at the inside wall of the vial. Slowly push the plunger to let the water trickle down the glass wall -- do NOT squirt directly onto the powder.
Once all water is added, gently swirl the vial in a slow circular motion. Never shake the vial, as this can damage the peptide bonds.
Continue swirling until the powder is completely dissolved and the solution is clear. If particles remain, let the vial sit for a few minutes and swirl again.
Label the vial with the date of reconstitution, the peptide name, and the concentration (e.g. 250mcg per 0.1mL).
Example calculation
Add the recommended volume of bacteriostatic water to the Natriuretic Peptide (ANP) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Dose calculation
Your dose of Natriuretic Peptide (ANP) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Pro tip
Always add the bacteriostatic water slowly, letting it run down the side of the vial. Never shake the vial -- swirl gently to avoid damaging the peptide.
Location
Site 01
Abdomen
Pinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
Site 02
Outer Thigh
Middle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
Site 03
Upper Arm
Back or outer area of the upper arm. This site may require assistance from another person for proper technique.
Rotate between 3 sites to prevent tissue buildup and ensure consistent absorption.
Pro tip
Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.
Step by step
Wash your hands thoroughly with soap and water before handling supplies
Clean the injection site with an alcohol swab and let it air dry completely
Pinch a fold of skin at the chosen injection site
Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
Inject the medication slowly and steadily over 5-10 seconds
Release the skin fold and remove the needle, applying gentle pressure with a clean swab
Rotate injection sites to prevent tissue irritation or lipodystrophy
Dispose of the needle safely in a sharps container—never recap or reuse needles
Pro tip
This peptide uses subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training. Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.
Timing
Optimal timing
Best time
Natriuretic Peptide (ANP) is administered intravenously in a clinical setting. [10] Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
With food?
IV administration of Natriuretic Peptide (ANP) is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
Stacking notes
Natriuretic Peptide (ANP) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intravenous infusion (continuous) - standard hospital delivery method—rotate sites if applicable
Maintain a consistent schedule for optimal results with Natriuretic Peptide (ANP). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Dosing tiers
Dose
0.0125 mcg/kg/min continuous infusion
Frequency
Continuous IV infusion
Duration
Up to 72 hours
Very low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
Dose
0.025-0.050 mcg/kg/min continuous infusion
Frequency
Continuous IV infusion
Duration
Up to 72 hours
Guideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.
Preservation
Before mixing
Store Natriuretic Peptide (ANP) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After mixing
Once reconstituted, Natriuretic Peptide (ANP) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Shelf life after mixing
Use within the timeframe specified on product labeling (typically 14-28 days refrigerated)
Signs of degradation
Discard the vial immediately if you notice any of these:
Solution appears cloudy, discolored, or contains visible particles (should be clear)
Product has been exposed to temperatures outside the recommended storage range
Product has been frozen (unless specifically designed for freeze-thaw stability)
Expiration date has passed or reconstituted solution has exceeded its use-by date
Unusual odor, color change, or visible contamination
Important
When to stop
Severe or worsening side effects that don't improve with dose adjustment or supportive care
Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
Your healthcare provider recommends discontinuation based on your clinical response
Development of any new medical condition that may be contraindicated with Natriuretic Peptide (ANP)
Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
Abnormal lab results or clinical markers that suggest adverse effects
Natriuretic Peptide (ANP) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Clean technique checklist
Wash hands thoroughly with soap and water before handling supplies
Swab vial tops and injection site with alcohol and let dry
Never touch the needle tip or allow it to contact non-sterile surfaces
Use a new syringe and needle for each injection
Dispose of used sharps in a proper sharps container
Store reconstituted peptides according to the storage instructions above
Published research
Honda S, Nagai T, Honda Y, et al. · 2025
Low-dose carperitide provided rapid hemodynamic improvements in acute heart failure patients but did not reduce long-term mortality or hospitalization when combined with standard treatment. The natriuretic peptide was most beneficial for immediate symptom relief.
Inamoto M, Kohyama N, Suzuki H, et al. · 2024
Patients under 75 years without prior diuretic use achieved the best diuretic response to carperitide, with 53.6% showing excellent results. Administering carperitide within 2 hours of a diuretic maximized urine output compared to longer delays.
Gorący-Rosik A, Fic M, Rosik J, et al. · 2025
Genetic variations in NPPA and NPPB genes predicted natriuretic peptide response and heart failure severity. These polymorphisms influenced ANP production and therapy effectiveness, supporting future personalized medicine approaches.
Nogi K, et al. · 2022
Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM · 2009
ANP is the 28-amino-acid peptide cleaved from proANP stored in atrial granules and released on atrial stretch from increased intravascular volume. It binds natriuretic peptide receptor-A, a transmembrane guanylyl cyclase that raises cGMP; NPR-A-dependent falls in blood pressure are achieved through natriuresis and diuresis, vasorelaxation, increased endothelial permeability and antagonism of the renin-angiotensin system, and ANP/NPR-A signalling also inhibits cardiac hypertrophy and remodelling. Plasma half-life of ANP in humans is approximately 2 min. Receptor dephosphorylation is the mechanism of desensitisation after prolonged ANP exposure. Synthetic full-length ANP, carperitide, was approved in Japan in 1995 for acute decompensated heart failure; in the United States clinical use of BNP rather than ANP was pursued.
Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH · 1986
After an intravenous bolus of 100 micrograms of alpha-human ANP in normal men, immunoreactive alpha-hANP fell exponentially over the first 10 min with t1/2 = 2.5 min and reached basal values by 30 min. Metabolic clearance rate during steady-state infusion was 2.4 L/min, volume of distribution 10.7 L, and the rapid-phase disappearance rate after stopping infusion 3.1 min.
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H · 1981
Intravenous injection of atrial, but not ventricular, myocardial extract produced a rapid and potent increase in renal sodium and water excretion in rats - the observation from which atrial natriuretic peptide was identified.
Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani Y · 2008
Prospective observational study of 1,832 acute heart failure syndrome patients with pulmonary congestion, dyspnoea and preserved systolic blood pressure treated with carperitide (alpha-human atrial natriuretic peptide) monotherapy, started at 0.025-0.05 microg/kg/min in 50.4%. Carperitide monotherapy restored the acute phase and improved the degree of dyspnoea on the modified Borg scale in 1,524 patients (83.2%). Adverse drug reactions occurred in 4.64%, most frequently hypotension (3.55%).
Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K · 2005
Six-year open-label registry of 3,777 acute heart failure patients treated with carperitide (alpha-human atrial natriuretic peptide) at a median 0.085 microg/kg/min for a median 65 h (interquartile 22-142 h); 82% were clinically improved. Adverse events occurred in 16.9%, the most frequent being blood pressure lowering (9.5%), which occurred in the first 3 h of infusion, with 96% of patients recovering or improving without specific treatment. Renal function disturbance, low blood pressure, age and Killip class predicted 7-day mortality.
Daiichi Sankyo / Pharmaceuticals and Medical Devices Agency (PMDA) · 2026
Approved in Japan for acute heart failure including acute exacerbation of chronic heart failure. Given as continuous intravenous infusion of 0.1 microg/kg/min, adjustable up to 0.2 microg/kg/min according to haemodynamics, with the patient monitored for blood pressure, heart rate, urine output, electrolytes and where possible pulmonary capillary wedge pressure, right atrial pressure and cardiac output; if haemodynamics and symptoms have not begun to improve 60 min after starting, another treatment should be used. Adverse reactions include blood pressure decrease 8.6%, hypotensive shock 0.2%, bradycardia 0.2%, electrolyte abnormality from excessive diuresis 1.8%, ventricular tachycardia 0.2%, ventricular fibrillation 0.1%, thrombocytopenia 0.1%, and (frequency not specified) nausea/vomiting, dizziness, flushing, atrial fibrillation and supraventricular tachycardia, raised BUN and creatinine, urticaria, rash and pruritus, and phlebitis at the injection site. Elimination half-life during 0.1 microg/kg/min infusion is 2.8 min (alpha phase) and 25.3 min (beta phase).
Hattori H, Minami Y, Mizuno M, et al. · 2012
Thirty-eight acute heart failure syndrome patients received 48-h continuous infusion of carperitide (0.0125-0.05 microg/kg/min) or nicorandil. After 48 h, systolic blood pressure fell 22.1 +/- 20.0% with carperitide versus 5.3 +/- 10.4% with nicorandil (P = 0.003), and improvement in estimated pulmonary capillary wedge pressure was greater with carperitide (38.2 +/- 14.5% vs 26.5 +/- 18.3%, P = 0.036), while improvement in estimated cardiac output was greater with nicorandil (52.1 +/- 33.5% vs 11.4 +/- 36.9%, P = 0.001).
Kajimoto K, Sashida Y, Minami Y, Yumino D, Kawarai H, Kasanuki H · 2009
In 24 patients with acute decompensated heart failure and left ventricular systolic dysfunction studied by right heart catheterisation, 17 (71%) responded to initial carperitide therapy with a 30% or greater fall in pulmonary capillary wedge pressure, or a fall below 16 mmHg, within 6 h of starting the infusion. Admission systolic blood pressure (cut-off 120 mmHg) and cardiac index predicted the response.
Kawase Y, Kadota K, Tada T, et al. · 2015
In 205 patients (mean age 75.6 years) hospitalised for acute decompensated heart failure and treated with low-dose carperitide (0.01-0.05 microg/kg/min), worsening renal function - a rise in serum creatinine of 0.3 mg/dl or more from admission - occurred within the first 24 h in 14 patients (7%). Independent predictors were hypotension (systolic blood pressure below 90 mmHg) within 12 h and serum creatinine on admission. Among patients with eGFR below 60 ml/min/1.73 m2, worsening renal function was more frequent when hypotension occurred (22.6% vs 4.4%).
Ayaz Z, Alsarkhi LN, Rawat A, et al. · 2025
Meta-analysis of six studies (2008-2025) of carperitide versus control in heart failure. All-cause mortality risk ratio 1.02 (95% CI 0.63-1.66), heart failure hospitalisation risk ratio 0.98 (95% CI 0.85-1.14). Carperitide received regulatory approval for acute heart failure in Japan in 1995, but adoption has remained geographically limited because of mixed efficacy results and the absence of large randomised trials meeting regulatory requirements in Western countries.
Head to head